DE69523295T2 - Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung - Google Patents

Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung

Info

Publication number
DE69523295T2
DE69523295T2 DE69523295T DE69523295T DE69523295T2 DE 69523295 T2 DE69523295 T2 DE 69523295T2 DE 69523295 T DE69523295 T DE 69523295T DE 69523295 T DE69523295 T DE 69523295T DE 69523295 T2 DE69523295 T2 DE 69523295T2
Authority
DE
Germany
Prior art keywords
ketamine
nasal
detoxification
pain control
ocular use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69523295T
Other languages
English (en)
Other versions
DE69523295D1 (de
Inventor
Stuart L Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69523295D1 publication Critical patent/DE69523295D1/de
Application granted granted Critical
Publication of DE69523295T2 publication Critical patent/DE69523295T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69523295T 1994-02-25 1995-02-24 Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung Expired - Lifetime DE69523295T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/201,756 US5543434A (en) 1994-02-25 1994-02-25 Nasal administration of ketamine to manage pain
PCT/US1995/002418 WO1995022965A2 (en) 1994-02-25 1995-02-24 Nasal and ocular administration of ketamine to manage pain and for detoxification

Publications (2)

Publication Number Publication Date
DE69523295D1 DE69523295D1 (de) 2001-11-22
DE69523295T2 true DE69523295T2 (de) 2002-07-11

Family

ID=22747152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69523295T Expired - Lifetime DE69523295T2 (de) 1994-02-25 1995-02-24 Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung

Country Status (11)

Country Link
US (1) US5543434A (de)
EP (1) EP0751766B1 (de)
JP (1) JP4729148B2 (de)
AT (1) ATE206913T1 (de)
CA (1) CA2184077C (de)
DE (1) DE69523295T2 (de)
DK (1) DK0751766T3 (de)
ES (1) ES2165910T3 (de)
MX (1) MX9603633A (de)
PT (1) PT751766E (de)
WO (1) WO1995022965A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
ES2205018T3 (es) * 1995-02-24 2004-05-01 Stuart Weg Administracion de ketamina para destoxificacion.
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
WO1997007750A1 (en) * 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US8017627B2 (en) 2000-07-31 2011-09-13 Nycomed Danmark Aps Fentanyl composition for nasal administration
WO2002013886A2 (en) * 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
NZ529417A (en) * 2001-05-24 2006-11-30 Alexza Pharmaceuticals Inc Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2452872A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
ES2292775T3 (es) * 2001-07-06 2008-03-16 Penwest Pharmaceuticals Co. Formulaciones de liberacion prolongada de oximorfona.
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2003051367A1 (en) * 2001-12-18 2003-06-26 Alexza Molecular Delivery Corporation Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US20070043112A1 (en) * 2003-10-21 2007-02-22 John Brew Use of non-opiates for the potentation of opiates
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2121088B1 (de) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
BR112015003796A2 (pt) * 2012-08-23 2017-07-04 L Weg Stuart composição ansiolítica, formulação e método de uso
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
WO2014169272A1 (en) 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
US20160074340A1 (en) 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US10166240B2 (en) 2015-06-19 2019-01-01 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
EP3813808A4 (de) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Verfahren zur behandlung von substanzmissbrauch
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
EP3976012B1 (de) 2019-05-31 2024-03-20 Afyx Therapeutics A/S Intranasale verabreichung von ketamin an patienten mit cluster-kopfschmerzen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334526A (en) * 1979-05-24 1982-06-15 Hamacher Edward N Method for administering a dissociative, unconscious type of anesthesia
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5132114A (en) * 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
CA2184077C (en) 2007-12-11
MX9603633A (es) 1998-01-31
WO1995022965A3 (en) 1995-12-21
DK0751766T3 (da) 2002-02-11
EP0751766A1 (de) 1997-01-08
DE69523295D1 (de) 2001-11-22
WO1995022965A2 (en) 1995-08-31
JP4729148B2 (ja) 2011-07-20
JPH10500664A (ja) 1998-01-20
ATE206913T1 (de) 2001-11-15
PT751766E (pt) 2002-04-29
EP0751766B1 (de) 2001-10-17
CA2184077A1 (en) 1995-08-31
US5543434A (en) 1996-08-06
ES2165910T3 (es) 2002-04-01

Similar Documents

Publication Publication Date Title
DE69523295D1 (de) Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung
DE69600307D1 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
DE69528247D1 (de) Regulierung der Wasserbehandlungsmitteldosierung, auf Basis von Betriebssystemspannungen
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69627153D1 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
DE69630947D1 (de) Mittel zur schmerzbehandlung
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE297396T1 (de) Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE9305147U1 (de) Trainingsgerät zur Behandlung von an Wahrnehmungsstörungen leidenden Patienten
LV11940A (lv) Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
IS1919B (is) Bensamíð til að meðhöndla taugahrörnunarsjúkdóma
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
NO990450D0 (no) Behandling av sinnslidelser
DE69806062T2 (de) Kombinationstherapie zur behandlung von aids
DE29516634U1 (de) Atemtherapiegerät
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
DE794791T1 (de) Neue therapeutische verwendung von superoxid-dismutasen
FR2694500B1 (fr) Nébuliseur polyvalent pour le traitement des voies respiratoires.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN